Strategic CDMO Novocol Pharma is a Cambridge, Ontario based sterile injectable CDMO with over 40 years of experience and a manufacturing focus on cartridge-based products, offering process scale up, analytical services, technology transfer and both biologic and small molecule production, presenting a broad contract manufacturing value proposition for potential clients.

Moderna Partnership Recent high-profile collaboration with Moderna for aseptic fill-finish, labeling and packaging of mRNA respiratory vaccines signals strong capability in complex sterile fill-finish and packaged end-to-end services, suggesting compelling cross-sell opportunities with other mRNA or biologics developers seeking Canadian manufacturing and regulatory readiness.

Regulatory Reach Global regulatory approvals spanning USA, Canada, Europe, Middle East and Asia indicate a robust quality system and international market access, enabling sales pitches to multinational pharma and biotechs seeking a single partner with broad regulatory coverage for global launch readiness.

Device Synergy Through affiliate Duoject Medical Systems, the company designs innovative drug delivery devices, presenting integrated solutions for combination products and device-enabled therapies, which can unlock cross-selling opportunities to customers needing both cartridges and compatible delivery systems.

Scale and Capacity With a workforce of 600+ and mid-market headcount, plus capabilities in high to low volume manufacturing and technology transfer, Novocol can position itself for clients at various scales, from early-stage development to commercial launch, especially for sterile injectable products and biologics with diverse manufacturing demands.